Higher comorbidities and early death in hospitalized African-American patients with Covid-19
Open Access
- 18 January 2021
- journal article
- research article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 21 (1), 1-11
- https://doi.org/10.1186/s12879-021-05782-9
Abstract
African-Americans/Blacks have suffered higher morbidity and mortality from COVID-19 than all other racial groups. This study aims to identify the causes of this health disparity, determine prognostic indicators, and assess efficacy of treatment interventions. We performed a retrospective cohort study of clinical features and laboratory data of COVID-19 patients admitted over a 52-day period at the height of the pandemic in the United States. This study was performed at an urban academic medical center in New York City, declared a COVID-only facility, serving a majority Black population. Of the 1103 consecutive patients who tested positive for COVID-19, 529 required hospitalization and were included in the study. 88% of patients were Black; and a majority (52%) were 61–80 years old with a mean body mass index in the “obese” range. 98% had one or more comorbidities. Hypertension was the most common (79%) pre-existing condition followed by diabetes mellitus (56%) and chronic kidney disease (17%). Patients with chronic kidney disease who received hemodialysis were found to have lower mortality, than those who did not receive it, suggesting benefit from hemodialysis Age > 60 years and coronary artery disease were independent predictors of mortality in multivariate analysis. Cox proportional hazards modeling for time to death demonstrated a significantly high ratio for COPD/Asthma, and favorable effects on outcomes for pre-admission ACE inhibitors and ARBs. CRP (180, 283 mg/L), LDH (551, 638 U/L), glucose (182, 163 mg/dL), procalcitonin (1.03, 1.68 ng/mL), and neutrophil:lymphocyte ratio (8.3:10.0) were predictive of mortality on admission and at 48–96 h. Of the 529 inpatients 48% died, and one third of them died within the first 3 days of admission. 159/529patients received invasive mechanical ventilation, of which 86% died and of the remaining 370 patients, 30% died. COVID-19 patients in our predominantly Black neighborhood had higher in-hospital mortality, likely due to higher prevalence of comorbidities. Early dialysis and pre-admission intake of ACE inhibitors/ARBs improved patient outcomes. Early escalation of care based on comorbidities and key laboratory indicators is critical for improving outcomes in African-American patients.Keywords
All Related Versions
This publication has 28 references indexed in Scilit:
- Hypertension and its severity or mortality in Coronavirus Disease 2019 (COVID-19): a pooled analysisPolish Archives of Internal Medicine, 2020
- Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective studyBMJ, 2020
- Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysisEuropean Respiratory Journal, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Tobacco Product Use and Cessation Indicators Among Adults — United States, 2018MMWR-Morbidity and Mortality Weekly Report, 2019
- Pneumonia in Patients with Chronic Obstructive Pulmonary DiseaseTuberculosis and Respiratory Diseases, 2018
- Blood pressure variability and multiple organ damage in primary hypertensionJournal of Human Hypertension, 2013
- Chapter 1: Definition and classification of CKDKidney International Supplements, 2013
- Section 5: Dialysis Interventions for Treatment of AKIKidney International Supplements, 2012
- Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2Circulation, 2005